Drug Trial Radar · NCT03840148
Safety and Efficacy Study of Cefepime/VNRX-5133 in Patients With Complicated Urinary Tract Infections
Last checked: Nov 19, 2026Latest source record: Jun 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
661
Actual
Start
Aug 7, 2019
Primary completion
Dec 14, 2021
Study completion Dec 14, 2021
Sponsor
- Lead sponsor
- Venatorx Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Feb 15, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the safety and efficacy of cefepime/VNRX-5133 compared with meropenem in both eradication of bacteria and in symptomatic response in patients with cUTIs.
Conditions
- Urinary Tract Infections
- Acute Pyelonephritis
Interventions
Cefepime/VNRX-5133 (taniborbactam)Drug
Cefepime/VNRX-5133 administered q8h intravenously (IV) over a 2-hour period for 7 days (up to 14 days for patients with bacteremia). Patients will also receive meropenem placebo administered via IV over 30 minutes.
MeropenemDrug
Meropenem will be administered q8h IV over 30 minutes for 7 days (up to 14 days for patients with bacteremia). Patients will also receive cefepime/VNRX-5133 placebo administered via IV over a 2-hour period.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Composite Success at Test of Cure (TOC) in the Microbiological Intent-to-treat (microITT) PopulationTime frame: Assessed at Test of Cure visit (occurred once per participant between Study Days 19 to 23)
Locations
78 sites in 15 countries. Site status is shown where the registry gives one.
Site 184003
Buena Park, California
Site 184002
Chula Vista, California
Site 184001
La Mesa, California
184012
Northridge, California
Site 103203
Córdoba, Argentina
Site 107601
Belo Horizonte, Brazil
Site 107608
São Paulo, Brazil
Site 110009
Gabrovo, Bulgaria
Site 110002
Pleven, Bulgaria
Site 110007
Plovdiv, Bulgaria
Site 110003
Rousse, Bulgaria
Site 110010
Sofia, Bulgaria
Site 110004
Sofia, Bulgaria
Site 110005
Sofia, Bulgaria
Site 110008
Sofia, Bulgaria
Site 110001
Veliko Tarnovo, Bulgaria
Site 156022
Baotou, China
Site 156002
Beijing, China
Site 156006
Beijing, China
Site 156015
Chendu, China
Site 156011
Chongqing, China
Site 156012
Chongqing, China
Site 156004
Dalian, China
Site 156030
Fujian, China
Site 156014
Guangdong, China
Site 156027
Guangdong, China
Site 156025
Guangzhou, China
Site 156018
Guiyang, China
Site 156003
Nanchang, China
Site 156005
Nanjing, China
Site 156008
Nanjing, China
Site 156007
Nanjing, China
Site 156013
Ningbo, China
Site 156028
Shandong, China
Site 156017
Shanghai, China
Site 156016
Shijiazhuang, China
Site 156020
Tianjin, China
Site 156029
Ürümqi, China
Site 156010
Xiamen, China
Site 119103
Split, Croatia
Showing 40 of 78 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.